CATALYST PHARMACEUTICALS INC (CPRX) Stock News

USA - NASDAQ:CPRX - US14888U1016 - Common Stock

20.97 USD

-0.04 (-0.19%)

Last: 10/30/2025, 8:00:47 PM

20.97 USD

0 (0%)

After Hours: 10/30/2025, 8:00:47 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CPRX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill

News Image

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Fundamentals and Technical Breakout Potential

4 days ago - By: Chartmill

News Image

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth

16 hours ago - By: Zacks Investment Research - Mentions: COLL

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

2 days ago - By: Zacks Investment Research - Mentions: ZTS

Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline

9 days ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

9 days ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

10 days ago - By: Benzinga

What Does the Market Think About Catalyst Pharmaceuticals Inc?

11 days ago - By: Chartmill

News Image

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals

22 days ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

22 days ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

a month ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

a month ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

2 months ago - By: Zacks Investment Research

Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?

2 months ago - By: Benzinga

How Is The Market Feeling About Catalyst Pharmaceuticals?

2 months ago - By: Zacks Investment Research

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

2 months ago - By: Yahoo Finance

Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035

2 months ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

2 months ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

2 months ago - By: Catalyst Pharmaceuticals, Inc.

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

2 months ago - By: Catalyst Pharmaceuticals, Inc.

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

2 months ago - By: Zacks Investment Research - Mentions: CRMD KNSA PHAR

Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

2 months ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

2 months ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

3 months ago - By: Zacks Investment Research

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock

3 months ago - By: Zacks Investment Research

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term

3 months ago - By: Zacks Investment Research - Mentions: CRMD ARVN IMCR

Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y

3 months ago - By: Zacks Investment Research - Mentions: RIGL

Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?

3 months ago - By: Zacks Investment Research

Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

3 months ago - By: Zacks Investment Research - Mentions: VYNE

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

3 months ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

3 months ago - By: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

3 months ago - By: Catalyst Pharmaceuticals, Inc.

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)